SNO 2026 Preview: New Directions in Glioma Care

Looking ahead to this year's SNO meeting, Lauren Schaff, MD, discusses how advances in other cancers could inform glioblastoma treatment, including the recent approval of a RAS inhibitor for metastatic pancreatic cancer. She looks forward to hearing more about this approach in Dr William Kaelin's talk, "Glioblastoma: Reasons for Hope From Other (Previously) Intractable Cancers." Dr Schaff also anticipates clinical trial updates on targeted therapies, immunotherapies, and antibody-drug conjugates, along with practical guidance on incorporating IDH inhibitors into patient care.In diagnostics, she highlights the recent FDA approval of an FET-PET imaging agent in the United States and an upcoming presentation on the added value of serial FET-PET imaging. She is interested in how this approach could help distinguish tumor progression from treatment-related changes and support monitoring over time. She also looks forward to updates on cell-free DNA biomarkers of response and how these emerging tools might be incorporated into clinical practice. Finally, Dr Schaff emphasizes that progress in neuro-oncology extends beyond developing better treatments to improving diagnosis, monitoring, and management of treatment-related complications. She welcomes the meeting's focus on neurocognitive outcomes and survivorship, underscoring the importance of preserving cognition, neurologic function, and patient independence.